LCH-I - A RANDOMIZED TRIAL OF ETOPOSIDE VS VINBLASTINE IN DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS
LCH-I - A RANDOMIZED TRIAL OF ETOPOSIDE VS VINBLASTINE IN DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS
复制标题
DOI：
10.1002/mpo.2950230207
复制
发表时间：
1994-01-01
期刊：
影响因子：
--
通讯作者：
NICHOLSON, HS
中科院分区：
文献类型：
--
作者：
LADISCH, S;GADNER, H;NICHOLSON, HS
组织细胞协会发起了一项针对朗格汉斯细胞组织细胞增多症 (LCH) 的国际随机试验。本报告回顾了 LCH-I 的基本原理、设计和进展，比较了依托泊苷 (VP-16) 和长春花碱治疗播散性 LCH 的效果。回顾了组织细胞增多症中依托泊苷相关（治疗诱发）恶性肿瘤风险的数据。现有证据表明应继续开展依托泊苷治疗 LCH 的研究。 (C) 1994 年 Wiley-Liss 公司
An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH-I, which compares etoposide (VP-16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide-associated (therapy-induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued. (C) 1994 Wiley-Liss, Inc.